# Linnaeus Therapeutics

Source: https://onco.cc/companies/linnaeus-therapeutics/  
OnCo record `linnaeus-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Linnaeus Therapeutics is a New Jersey biotech whose oral drug LNS8801 activates the oestrogen receptor GPER, a pathway that pushes melanoma cells to stop dividing and become visible to the immune system.

## Summary

Linnaeus Therapeutics develops LNS8801, an orally available agonist of the G protein-coupled oestrogen receptor (GPER), based on University of Pennsylvania research showing that GPER activation drives melanoma differentiation and lowers c-Myc. LNS8801 has been tested alone and with pembrolizumab in phase 1/2 trials in cutaneous melanoma and uveal melanoma, including patients who had progressed on checkpoint inhibitors.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Linnaeus Therapeutics, Inc.
- Tags: drug-maker
- HQ: Haddonfield, New Jersey
- Type: biotech

## Connected records

- drugs: [LNS8801](https://onco.cc/drugs/lns8801/)

---
JSON: https://onco.cc/api/v1/entities/linnaeus-therapeutics.json